Table 3.
Multivariable analysis for the association between patient and tumor characteristics with overall survival
| Hazard Ratio | HR P-value | ||
|---|---|---|---|
| Treatment group | Surgery | 1.27 (1.11–1.44)* | <0.001 |
| Bladder preservation | - | - | |
| Age at Diagnosis | 1.03 (1.02–1.03) | <.001 | |
| T-stage | 2 | 0.78 (0.71–0.85) | <.001 |
| 3 | - | - | |
| Charlson-Deyo Score | 0 | 0.61 (0.55–0.68) | <.001 |
| 1 | 0.77 (0.69–0.87) | <.001 | |
| 2 | - | - | |
| Primary site | Trigone of bladder | 0.90 (0.79–1.04) | 0.146 |
| Dome of bladder | 1.02 (0.86–1.20) | 0.810 | |
| Bladder wall | 0.80 (0.74–0.86) | <.001 | |
| Bladder neck and ureteric orifice | 0.69 (0.57–0.83) | <.001 | |
| Bladder NOS | - | - | |
| Facility Type | Academic/Research Program | - | - |
| Comprehensive Community Cancer Program | 1.15 (1.07–1.23) | <.001 | |
| Integrated Network Cancer Program | 1.13 (0.99–1.30) | 0.067 | |
| Other specified types of cancer programs | 1.19 (0.69–2.06) | 0.528 | |
| Community Cancer Program | 1.18 (1.04–1.32) | 0.007 |
*
Hazard ratio for surgery vs. CRT is initially significant favoring CRT and decreases by a factor of 0.85 (95% CI: 0.81–0.89) per year for surviving patients